Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1401-1420 of 1,738 trials

CD19+ Lymphoid Disease: CAR T-Cell Therapy

We are studying a new treatment using modified T cells for patients with relapsed or refractory CD19+ lymphoid diseases like leukemia and lymphoma. The goal is to see if this approach can safely reduce cancer and improve patient outcomes.

Acute Lymphoblastic Leukemia (ALL) RecurrentNon-Hodgkin's Lymphoma (NHL) Refractory>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Ovarian Cancer: Olaparib Maintenance Therapy

We are studying the effects of Olaparib as a maintenance treatment for patients with newly diagnosed advanced ovarian cancer. This trial aims to understand its safety and how it may improve patient outcomes.

Advanced Ovarian Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGynecology and ObstetricsOncology

Ovarian Cancer: Olaparib Treatment Study

We are investigating the effects of Olaparib in patients with recurrent ovarian cancer who do not have BRCA mutations. The goal is to see if it helps maintain treatment benefits after initial therapy and to understand its safety and effectiveness.

Recurrent Ovarian CancerEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Tardive Dyskinesia: Testing ADE513

We are studying a new medication to see if it helps reduce involuntary movements in people with moderate to severe tardive dyskinesia. The trial also looks at the safety and tolerability of this treatment.

Tardive Dyskinesia3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesNeurologyPsychiatry

Corticobasal Syndrome: Glycerol Phenylbutyrate Study

We are investigating whether glycerol phenylbutyrate can lower nerve damage markers in patients with corticobasal syndrome. This study will also look at the safety and tolerability of the treatment.

Corticobasal Syndrome6-12 monthsEfficacy phase (II)≤5 visitsStandard MedicinesCost ReimbursementInternal MedicineNeurology

ADCE-D01 for Metastatic Soft Tissue Sarcoma

We are testing a new treatment called ADCE-D01 in patients with metastatic or unresectable soft tissue sarcoma. The study aims to evaluate its safety and how well it may help fight the cancer.

Soft Tissue Sarcoma1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

SAPHO Syndrome: Etanercept Treatment Study

We are testing the safety and effectiveness of etanercept in patients with SAPHO syndrome who are already on standard treatments. This study aims to explore new treatment options for better management of their condition.

SAPHO Syndrome6-12 monthsEfficacy phase (II)Confirmation phase (III)Standard MedicinesInfectious DiseasesRheumatology

Lymphoma Treatment: Loncastuximab Tesirine

We are studying a new treatment for patients with relapsed or refractory diffuse large B-cell lymphoma or high-grade B-cell lymphoma after CAR T-cell therapy. The goal is to see if it improves response rates and survival outcomes.

B-cell Non-Hodgkin's Lymphoma>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Psilocybin for Chemotherapy-Induced Pain Relief

We are exploring whether psilocybin can help reduce chronic pain for patients recovering from chemotherapy. The goal is to see if it improves daily activities affected by pain.

Chemotherapy-Induced Peripheral Neuropathy3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyOncologyOtolaryngology

ALS and TIA: Hyperpolarized Pyruvate MRI Study

We are testing a new MRI method to see if it can help identify metabolic problems in patients with Amyotrophic Lateral Sclerosis and Transient Ischemic Attack. This may improve our understanding of these conditions.

Amyotrophic Lateral Sclerosis (ALS)Transient Ischemic Attack (TIA)>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementNeurology

ORE-001 for Underweight Elderly Individuals

We are studying whether ORE-001, an oral medication, can help underweight elderly people increase their food intake and improve their health. The trial compares its effects to a placebo to assess safety and overall well-being.

Underweight3-6 monthsEfficacy phase (II)≤5 visitsStandard MedicinesEndocrinologyGastroenterologyInternal Medicine

Monalizumab for Acute Myeloid Leukemia and Myelodysplastic Syndrome

We are studying the safety and effectiveness of Monalizumab in patients with acute myeloid leukemia or myelodysplastic syndrome receiving a stem cell transplant. This trial aims to understand its impact on recovery and survival.

Acute Myeloid Leukemia1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Crohn's Disease: SAR442970 Study

We are investigating the effects of a new medication, SAR442970, on adults with moderate to severe Crohn's disease. The study aims to see if it helps improve symptoms and overall health compared to a placebo.

Crohn's Disease1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterology

Advanced Non-Small Cell Lung Cancer: MaaT033 and Cemiplimab

We are studying a new treatment combining fecal microbiotherapy with Cemiplimab for patients with advanced NSCLC who have not responded to previous therapies. This trial aims to see if this combination can improve disease control and overall health compared to standard treatments.

Advanced Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Brain Injury and Concussion: Tau Tracer Study

We are investigating whether tau levels in the brain are higher in patients with brain injuries and athletes with concussion symptoms. The study also looks at how these brain levels relate to tau found in blood samples.

Cerebral ConcussionIntracerebral HemorrhageTraumatic Brain Injury>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesInternal MedicineNeurology

Golcadomide for Brain Lymphoma: A Phase 2 Study

We are studying the effectiveness of golcadomide in patients with relapsed or refractory large B-cell lymphoma in the brain. The goal is to see if it can help achieve remission and improve overall health.

Diffuse Large B-Cell LymphomaSecondary Central Nervous System LymphomaRelapsed Primary Large B-Cell Lymphoma of the Central Nervous System1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesNeurologyOncology

Alzheimer's Disease: Tau and Amyloid Brain Imaging Study

We are investigating how tau protein deposits in the brain can help distinguish between Alzheimer's disease and other conditions. This study may provide insights into early diagnosis and disease progression.

Alzheimer's Disease>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteNeurology

Advanced Melanoma: New Treatment Combination

We are studying a new treatment approach for patients with advanced melanoma, combining immune therapies to see if it improves outcomes and reduces side effects. This trial aims to understand how well these treatments work together.

Solid Tumors3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncology

Multiple Myeloma: Fluciclovine PET/CT Imaging Study

We are investigating a new imaging method for multiple myeloma patients to see how it compares to standard imaging. This study aims to understand its effectiveness and safety in detecting the disease.

Multiple MyelomaEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOncologyOtolaryngology

Multiple Myeloma: Isatuximab Combination Therapy

We are studying a new treatment combining isatuximab with other medications for patients with newly diagnosed multiple myeloma who cannot undergo a transplant. The goal is to see how effective and safe this treatment is, and how it impacts patients' lives.

Newly Diagnosed Transplant Ineligible Multiple Myeloma>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesHematologyOncology